FDA rejects Coherus' biosimilar for Amgen's Neulasta

(Reuters) - Coherus BioSciences Inc said on Monday the U.S. Food and Drug Administration (FDA) denied the approval of its biosimilar for Amgen Inc's blockbuster treatment, Neulasta, which fights infections in cancer patients.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news